世界の細胞治療市場2023年-2028年:成長・動向・新型コロナの影響・市場予測

【英語タイトル】Cell Therapy Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)

Mordor Intelligenceが出版した調査資料(MOR23MAR0013)・商品コード:MOR23MAR0013
・発行会社(調査会社):Mordor Intelligence
・発行日:2023年1月23日
・ページ数:115
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後2-3営業日)
・調査対象地域:アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、中東、南アフリカ、ブラジル、アルゼンチン
・産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD4,750 ⇒換算¥703,000見積依頼/購入/質問フォーム
Corporate License(複数拠点内で共有可)USD8,750 ⇒換算¥1,295,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・送付(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
❖ レポートの概要 ❖

Mordor Intelligence社の本調査レポートでは、世界の細胞治療市場規模が、予測期間中に年平均17.05%で成長すると予測しています。本レポートは、細胞治療の世界市場について調べ、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、種類別(自己、同種異系)分析、治療別(間葉系幹細胞療法、線維芽細胞療法、造血幹細胞療法、その他)分析、用途別(筋骨格、悪性腫瘍、心臓血管、皮膚&創傷、その他)分析、地域別(アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、中東、南アフリカ、ブラジル、アルゼンチン)分析、競争状況、市場機会・将来の動向などを以下の構成でまとめています。また、Anterogen Co. Ltd、Tego Science、Chiesi Farmaceutici SpA、Corestem Inc.、Pharmicell Co. Ltd、Fibrocell Technologies Inc.、Nipro Corporation、MEDIPOST Co. Ltd、TiGenix (Takeda Pharmaceuticals)、Stempeutics Research Pvt. Ltd、Gilead Sciences Inc. (Kite Pharma Inc.)、Allogene Therapeutics Inc.、Novartis AG、Vericel Corporation、Organogenesis Inc.などの企業情報が含まれています。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・市場動向
・世界の細胞治療市場規模:種類別
- 自己細胞治療の市場規模
- 同種異系細胞治療の市場規模
・世界の細胞治療市場規模:治療別
- 間葉系幹細胞療法の市場規模
- 線維芽細胞療法の市場規模
- 造血幹細胞療法の市場規模
- その他治療の市場規模
・世界の細胞治療市場規模:用途別
- 筋骨格における市場規模
- 悪性腫瘍における市場規模
- 心臓血管における市場規模
- 皮膚&創傷における市場規模
- その他用途における市場規模
・世界の細胞治療市場規模:地域別
- 北米の細胞治療市場規模
アメリカの細胞治療市場規模
カナダの細胞治療市場規模
メキシコの細胞治療市場規模

- ヨーロッパの細胞治療市場規模
ドイツの細胞治療市場規模
イギリスの細胞治療市場規模
フランスの細胞治療市場規模

- アジア太平洋の細胞治療市場規模
中国の細胞治療市場規模
日本の細胞治療市場規模
インドの細胞治療市場規模

- 中東/南米の細胞治療市場規模
南アフリカの細胞治療市場規模
ブラジルの細胞治療市場規模
アルゼンチンの細胞治療市場規模

- その他地域の細胞治療市場規模
・競争状況
・市場機会・将来の動向

The cell therapy market is expected to witness a CAGR of 17.05% over the forecast period.

The impact of the COVID-19 pandemic on the cell therapy market is expected to be significant as most companies have been focusing on the development of cell-based therapies for COVID-19 treatment. For instance, in April 2020, Calidi Biotherapeutics Inc. revealed that the Investigational New Drug (IND) application submitted by its partner, Personalized Stem Cells Inc. (PSC), received the Food and Drug Administration approval for the treatment of COVID-19 and pneumonia patients using stem cell therapy. The impact of COVID-19 is also expected to have a positive impact on the studied market as most pharmaceutical, biotechnology, and research institutes have been focusing on the development of cell therapy-based treatment against COVID-19. For instance, according to the study published in Stem Cell Research & Therapy volume on ‘When stem cells meet COVID-19: recent advances, challenges and future perspectives’ published in January 2022, stem cell therapy and stem cell-derived organoid models have got a lot of attention as a new treatment and research method for COVID-19, and stem cells play a role in the battle against COVID-19. This will open up further opportunities for the market players to launch new products, which is expected to drive the market growth during the forecast period.

The cell therapy market is anticipated to witness healthy growth due to the increasing prevalence of chronic conditions, rising adoption of regenerative medicine, and rise in the number of clinical studies about the development of cellular therapies.

Chronic diseases and conditions are on the rise worldwide. As per the International Diabetes Federation Diabetes Altas, in 2021, nearly 573 million adults globally were living with diabetes worldwide, and the number is expected to reach 643 million by 2030 and 783 million by 2045.

Therefore, the increasing prevalence of chronic conditions, government assistance, and numerous companies investing heavily in stem cell therapy research and development are predicted to stimulate industry growth. The proven effectiveness of cell therapy products, coupled with the increasingly favorable guidelines on cell therapy research and manufacturing, is likely to positively impact the market growth over the forecast period. On the other hand, the high cost associated with cell therapies is expected to hinder market growth.

Cell Therapy Market Trends

The Allogeneic Therapies Segment is Expected to Account for a Significant Share in the Cell Therapy Market

Allogeneic therapies rely on a single source of cells to treat many patients. They increase the risk of eliciting an immune response within a patient, and immunosuppressive therapies are sometimes administered in combination with allogeneic products. Therefore, the increasing inclination of physicians toward the therapeutic use of allogeneic therapies and rising awareness about the use of cord cells and tissues across various therapeutic areas are some of the major factors driving the growth. Allogenic cells have benefits as they produce their own immune stem cells that kill the cancer cells that remain even after high-dose treatment with cytotoxic drugs. This response is called a graft-versus-cancer effect, and this is used in the prevention or treatment of cancer relapse. The aforementioned factors are expected to drive the market over the forecast period.

The rising number of clinical trials required to gain regulatory approval for new medications to advance patient care is expected to boost the segment growth. For instance, ALLO-501, ALLO-501A, ALLO-715, UCART19, and UCART19 by Allogene provide growth opportunities for the segmental growth.

Moreover, in January 2020, Allogene Therapeutics Inc. and SpringWorks Therapeutics Inc. entered a clinical trial collaboration agreement for the evaluation of ALLO-715, along with Nirogacestat, in multiple myeloma patients.

Thus, owing to the rising number of research studies on allogenic therapy for cancer and associated benefits, the studied segment is anticipated to register steady growth over the forecast period.

North America is Expected to Dominate the Market Over the Forecast Period

North America is estimated to retain the largest share of the cell therapy market due to the presence of a strong regulatory framework to promote cellular therapy development, the existence of industry key players, and the presence of leading universities that support the research activities in the United States. Factors attributing to the high growth of the market in the region include the increasing prevalence of chronic conditions, rising adoption of regenerative medicine, and rise in the number of clinical studies about the development of cellular therapies.

Rising investments from market players for the development and expansion of cell-based therapies in the United States are expected to drive the market in North America. For instance, in January 2022, Cellino Biotech, an autonomous cell therapy manufacturing company, raised USD 80 million Series A financing round. Cellino plans to expand access to stem cell-based therapies with the intention to build the first autonomous human cell foundry in 2025. The applications of stem cell technologies in the treatment of diseases have ultimately increased the overall adoption rate of these technologies across the world. This has led to increased investments by market players in the development of novel therapies in this area. ​

Furthermore, improved results of cell therapy products for the treatment of cancers will lead to a rise in product development, which is expected to drive the growth of this market. For instance, in June 2021, Gilead’s Yescarta CAR T-cell therapy improved event-free survival by 60% in second-line relapsed or refractory large B-cell lymphoma patients. In addition, in June 2021, Bristol-Myers Squibb reported positive topline results from the phase 3 TRANSFORM Trial evaluating Breyanzi (lisocabtagene maraleucel) in second-line relapsed or refractory large B-cell lymphoma.

Therefore, rising investments and research initiatives by the key market players and positive results of cell therapies are the factors expected to drive the growth of this market in North America.

Cell Therapy Market Competitor Analysis

The cell therapy market is moderately competitive, with the presence of a considerable number of companies. The major companies in this market are evolving through various strategies such as investment in research and development, acquisitions, partnerships, and collaborations to secure their market positions. The major companies of the studied market are Pharmicell Co. Ltd, Corestem Inc., Chiesi Farmaceutici SpA, Tegoscience, Anterogen Co. Ltd, and TiGenix (Takeda Pharmaceuticals), among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support
❖ レポートの目次 ❖

1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Chronic Conditions
4.2.2 Rising Adoption of Regenerative Medicine
4.2.3 Rise in Number of Clinical Studies Pertaining to the Development of Cellular Therapies
4.3 Market Restraints
4.3.1 High Cost of Therapies
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value – USD million)
5.1 Type
5.1.1 Autologous
5.1.2 Allogeneic
5.2 Therapy
5.2.1 Mesenchymal Stem Cell Therapy
5.2.2 Fibroblast Cell Therapy
5.2.3 Hematopoietic Stem Cell Therapy
5.2.4 Other Therapies
5.3 Application
5.3.1 Musculoskeletal
5.3.2 Malignancies
5.3.3 Cardiovascular
5.3.4 Dermatology and Wounds
5.3.5 Other Applications
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle-East
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle-East
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Anterogen Co. Ltd
6.1.2 Tego Science
6.1.3 Chiesi Farmaceutici SpA
6.1.4 Corestem Inc.
6.1.5 Pharmicell Co. Ltd
6.1.6 Fibrocell Technologies Inc.
6.1.7 Nipro Corporation
6.1.8 MEDIPOST Co. Ltd
6.1.9 TiGenix (Takeda Pharmaceuticals)
6.1.10 Stempeutics Research Pvt. Ltd
6.1.11 Gilead Sciences Inc. (Kite Pharma Inc.)
6.1.12 Allogene Therapeutics Inc.
6.1.13 Novartis AG
6.1.14 Vericel Corporation
6.1.15 Organogenesis Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS



★調査レポート[世界の細胞治療市場2023年-2028年:成長・動向・新型コロナの影響・市場予測] (コード:MOR23MAR0013)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の細胞治療市場2023年-2028年:成長・動向・新型コロナの影響・市場予測]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆